A reduced CD8+ lymphocyte subset distinguishes patients with polymyalgia rheumatica and temporal arteritis from patients with other diseases

Clinical and Experimental Rheumatology

Volumn 16, Issue 2, 1998, Pages 155-160

  Elling, P ^a   Olsson, A T ^b   Elling, H ^b  

^a RANDERS REGIONAL HOSPITAL   (Denmark)

^b VIBORG HOSPITAL   (Denmark)

Author keywords

CD8+ lymphocytes; Diagnostic test; Giant cell arteritis

Indexed keywords

ADULT; AGED; ARTICLE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; GIANT CELL ARTERITIS; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATIC POLYMYALGIA; T LYMPHOCYTE SUBPOPULATION; TEMPORAL ARTERITIS;

BLOOD CELLS; CD8-POSITIVE T-LYMPHOCYTES; DIAGNOSIS, DIFFERENTIAL; HUMANS; LYMPHOCYTE COUNT; POLYMYALGIA RHEUMATICA; RHEUMATIC DISEASES; ROC CURVE; SENSITIVITY AND SPECIFICITY; TEMPORAL ARTERITIS; VASCULITIS;

EID: 0031775966     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. SALVARANI C, SHERINE EG, O'FALLON WM, HUNDER GG: Epidemiology of Polymyalgia rheumatica in Olmsted County, Minnesota, 1970-1991. Arthritis Rheum 1995; 38: 369-73.
2. ELLING P, OLSSON AT, ELLING H: Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; association with epidemics of Mycoplasma pneumoniae infection. J Rheumatol 1996; 23: 112-9.
3. ELLIS ME, RALSTON WS: The ESR in diagnosis of the polymyalgia rheumatica/giant cell arteritis syndrome. Ann Rheum Dis 1983; 42: 168-70.
4. OLSSON AT, ELLING H, ELLING P: Frequency of a normal ESR in patients with active, untreated arteritis temporalis and polymyalgia rheumatica. Arthritis Rheum 1997; 40: 191-192
5. BENLAHRACHE C, SEGOND P, AUQUIER L, BOURET JP: Decrease of the OKT8 positive cell subset in polymyalgia rheumatica. Lack of correlation with disease activity. Arthritis Rheum 1983; 26: 1472-80.
6. CHELAZZI G, BROGGINI M: Abnormalities of peripheral blood lymphocytes subsets in polymyalgia rheumatica. Clin Exp Rheumatol 1984; 2: 333-6.
7. ELLING H, ELLING P: Decreased level of suppressor/cytotoxic T-cells (OKT8+) in polymyalgia rheumatica and arteritis temporalis: Relation to disease activity. J Rheumatol 1985; 12: 306-9.
8. ELLING P, OLSSON AT, ELLING H: CD8+T lymphocyte subset in giant cell arteritis and related disorders. J Rheumatol 1990; 17: 225-7.
9. ARNOLD M, CORRIGALL V, PANAYI GS: The sensitivity and specificity of reduced CD8 lymphocyte levels in the diagnosis of polymyalgia rheumatica/giant cells arteritis. Clin Exp Rheumatol 1993; 11: 629-34.
10. SALVARANI C, BOIARDI L, MACCHIONI P et al.: Role of peripheral CD8 lymphocytes and soluble IL-2 receptor in predicting the duration of corticosteroid treatment in polymyalgia rheumatica and giant cell arteritis. Ann Rheum Dis 1995; 54: 640-4.
11. FOUNTAIN GD, KEOGAN MT, BROWN DL, HAZLEMAN BL: Circulating T cell subtypes in polymyalgia rheumatica and giant cell arteritis: variation in the percentage of CD8+ cells with prednisolone treatment. Ann Rheum Dis 1993; 52: 730-3.
12. ANDERSSON R, HANSSON GK, SØDERSTRØM T, JONSSON R, BENGTSSON BA, NORDBORG E: HLA-DR expression in the vascular lesion and circulating T lymphocytes of patients with giant cell arteritis. Clin Exp Immunol 1988; 73: 82-7.
13. BOIARDI L, SALVARANI C, MACCHIONI O et al.: CD8 lymphocyte subsets in active polymyalgia rheumatica: Comparison with elderly-onset and adult rheumatoid arthritis and influence of prednisone therapy. Br J Rheumatol 1996; 35: 642-8.
14. ELLING P, OLSON AT, ELLING H: The Cambridge dilemma. Ann Rheum Dis 1994; 53: 780-1.
15. JOHANSEN MK, ELLING P, OLSSON AT, ELLING H: A genetic approach to the pathogenesis of giant cell arteritis. Depletion of CD8+ T cells in first degree relatives of patients with polymyalgia rheumatica and arteritis temporalis. Clin Exp Rheumatol 1995; 13: 745-7
16. GRINER K: Principles of test selection and use. Ann Intern Med 1981; 94: 559-63.
17. DAVENPORT A, LOCK RJ, WALLINGTON TB, FEEST TG: Clinical significance of anti-neutrophil cytoplasm antibodies detected by standardized indirect immunofluorescence assay. Q J Med 1994; 87: 291-9.
18. VISSER H, GELINCK LBS, KAMPFRAATH AH, BREEDVELD FC: Diagnostic and prognostic characteristic of the enzyme linked immunosorbent rheumatoid factor assays in rheumatoid arthritis. Ann Rheum Dis 1996; 55: 157-61.
19. MONACO JJ: A molecular model of MHC class-1 -restricted antigen processing. Immunol Today 1992; 13: 173-9.
20. ACCOLLA RS, ADORINI L, SARTORIS S, SINIGAGLIA F, GUARDIOLA J: MHC: Orchestrating the immune response. Immunology Today 1995; 16: 8-11.
21. PEARCE RB, TRIGLER L, SVAASAND EK, PETERSON CM: Polymorphism in the mouse TAP-1 gene. Association with abnormal CD8+ T cell development in the non-obese non-diabetic mouse. J Immunol 1993; 151: 5338-47.
22. ARPAIA E, SHARAR M, DADI H, COHEN A, ROIFMAN CM: Defective T cell receptor signaling and CD8+ thymic selection in humans lacking ZAP-70 kinase. Cell 1994; 76: 947-58.
23. DE LA SALLE H, HANAU D, FRICKER D et al.: Homozygous human TAP peptide transporter mutation in HLA class 1 deficiency. Science 1994; 265: 237-41.
24. PLOEGH HL: Trafficking and assembly of MHC molecules. How viruses elude the immune system. The Immunologist 1995; 3: 226-40.
25. CIMMINO MA, GRAZI G, BALISTRERI M, ACCARDO S: Increased prevalence of antibodies to adenovirus and respiratory syncytial virus in polymyalgia rheumatica. Clin Exp Rheumatol 1993; 11: 309-13.